Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

Similar articles for PubMed (Select 23370364)

1.

A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.

Ellis PM, Jungnelius U, Zhang J, Fandi A, Beck R, Shepherd FA.

J Thorac Oncol. 2013 Apr;8(4):423-8. doi: 10.1097/JTO.0b013e318282707b.

PMID:
23370364
2.

NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.

Ellis PM, Shepherd FA, Laurie SA, Goss GD, Olivo M, Powers J, Seymour L, Bradbury PA.

J Thorac Oncol. 2014 Mar;9(3):410-3. doi: 10.1097/JTO.0000000000000058.

PMID:
24518092
3.

A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.

Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA Jr.

Clin Cancer Res. 1999 Nov;5(11):3419-24.

4.

Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.

De Marinis F, Migliorino MR, Paoluzzi L, Portalone L, Ariganello O, Cortesi E, Gamucci T, Gasperoni S, Cipri A, Martelli O, Nelli F; Foundation for Oncological Research.

Lung Cancer. 2003 Mar;39(3):331-8.

PMID:
12609572
5.

Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.

Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK.

Cancer. 1998 Jan 15;82(2):301-8.

PMID:
9445186
6.

Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.

Sorensen M, Lassen U, Jensen PB, Østerlind K, Jeppesen N, Jensen BB, Mellemgaard A, Rytter C, Langer SW.

J Thorac Oncol. 2008 Aug;3(8):902-6. doi: 10.1097/JTO.0b013e31817e0f58.

PMID:
18670309
7.

Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.

William WN Jr, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS.

Cancer. 2010 May 15;116(10):2409-15. doi: 10.1002/cncr.25076.

8.

Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.

Zhou ZT, Zhou FX, Wei Q, Zou LY, Qin BF, Peng XS.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1027-32. doi: 10.1007/s00280-011-1576-1. Epub 2011 Feb 17.

PMID:
21327933
9.

A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.

Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.

Cancer. 2002 Oct 1;95(7):1511-9.

10.

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.

Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N, Dimitrijevic S, Urva S, Pylvaenaeinen I, Petrovic K, Johnson BE.

Ann Oncol. 2014 Feb;25(2):505-11. doi: 10.1093/annonc/mdt535. Epub 2013 Dec 23.

11.

Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.

Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KM, Shin DM, Hong WK.

J Clin Oncol. 1999 Aug;17(8):2309-15.

PMID:
10561292
12.

A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Garst J, Herndon JE 2nd, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Maravich-May D, Anderson E, Crawford J.

Clin Drug Investig. 2006;26(5):257-66.

PMID:
17163259
13.

A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.

Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonicolis J, Georgoulias V; Greek Lung Cancer Cooperative Group.

Ann Oncol. 2001 Apr;12(4):463-70.

14.

Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.

Mavroudis D, Veslemes M, Kouroussis Ch, Tzanakis N, Ferdoutsis E, Toumbis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulias V; Hellenic Oncology Research Group.

Lung Cancer. 2002 Oct;38(1):59-63.

PMID:
12367794
15.

Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.

Xenidis N, Kotsakis A, Kalykaki A, Christophyllakis Ch, Giassas S, Kentepozidis N, Polyzos A, Chelis L, Vardakis N, Vamvakas L, Georgoulias V, Kakolyris S.

Lung Cancer. 2010 Jun;68(3):450-4. doi: 10.1016/j.lungcan.2009.08.012. Epub 2009 Sep 23.

PMID:
19783319
17.

E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.

Owonikoko TK, Aisner J, Wang XV, Dahlberg SE, Rubin EH, Ramalingam SS, Gounder M, Rausch PG, Axelrod RS, Schiller JH.

Cancer Chemother Pharmacol. 2014 Jan;73(1):171-80. doi: 10.1007/s00280-013-2338-z. Epub 2013 Nov 28.

PMID:
24288121
18.

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.

Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, Berger MS.

Br J Cancer. 2012 Feb 28;106(5):839-45. doi: 10.1038/bjc.2012.21. Epub 2012 Feb 14.

19.
20.

A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.

Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS.

Clin Cancer Res. 2003 Jun;9(6):2085-91.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk